Clinical data and prognostic factors
Variable . | All patients . | Less than 23% HLA-G—positive cells . | 23% or more HLA-G—positive cells . | P* . |
|---|---|---|---|---|
| No. of patients (%) | 47 | 37 (79) | 10 (21) | |
| Age at diagnosis, y | 61 (30-88)† | 60.5 (30-80)† | 62.5 (41-88)† | NS |
| Male (%) | 37 (79)‡ | 29 (78)‡ | 8 (80)‡ | NS |
| Binet stage at diagnosis (%) | ||||
| A | 37 (79) | 30 (81) | 7 (70) | NS |
| B | 6 (13) | 5 (14) | 1 (10) | |
| C | 4 (9) | 2 (5) | 2 (20) | |
| Hemoglobin, g/dL, n = 47 | 13.05 ± 1.75§ | 13.35 ± 1.6§ | 11.94 ± 1.87§ | .023 |
| Platelets/nL, n = 47 | 147 ± 65§ | 153 ± 64§ | 124 ± 68§ | NS |
| Leukocytes/nL, n = 47 | 56.96 ± 64.5§ | 58.5 ± 69.1§ | 51.1 ± 45.6§ | NS |
| Neutrophils/nL, n = 46 | 4.8 ± 4.3§ | 5.3 ± 4.4§ | 3.0 ± 3.1§ | .06 |
| Lymphocytes/nL, n = 46 | 50.2 ± 61.0§ | 51.2 ± 65.7§ | 46.6 ± 42.4§ | NS |
| Monocytes/nL; n = 46 | 1.4 ± 2.6§ | 1.5 ± 2.9§ | 1.1 ± 1.1§ | NS |
| CD38+ leukemia (%), n = 47 | 24 (51) | 17 (46) | 7 (70) | NS |
| ZAP-70+ leukemia (%), n = 42 | 19 (45) | 15 (45) | 4 (44) | NS |
| β2-microglobulin, mg/L, n = 45 | 4.0 ± 2.2§ | 3.8 ± 2.0§ | 5.0 ± 2.5§ | NS |
| Thymidine kinase, U/L, n = 32 | 28.5 ± 34.5§ | 22.3 ± 29.3§ | 55.8 ± 44.8§ | .055 |
Variable . | All patients . | Less than 23% HLA-G—positive cells . | 23% or more HLA-G—positive cells . | P* . |
|---|---|---|---|---|
| No. of patients (%) | 47 | 37 (79) | 10 (21) | |
| Age at diagnosis, y | 61 (30-88)† | 60.5 (30-80)† | 62.5 (41-88)† | NS |
| Male (%) | 37 (79)‡ | 29 (78)‡ | 8 (80)‡ | NS |
| Binet stage at diagnosis (%) | ||||
| A | 37 (79) | 30 (81) | 7 (70) | NS |
| B | 6 (13) | 5 (14) | 1 (10) | |
| C | 4 (9) | 2 (5) | 2 (20) | |
| Hemoglobin, g/dL, n = 47 | 13.05 ± 1.75§ | 13.35 ± 1.6§ | 11.94 ± 1.87§ | .023 |
| Platelets/nL, n = 47 | 147 ± 65§ | 153 ± 64§ | 124 ± 68§ | NS |
| Leukocytes/nL, n = 47 | 56.96 ± 64.5§ | 58.5 ± 69.1§ | 51.1 ± 45.6§ | NS |
| Neutrophils/nL, n = 46 | 4.8 ± 4.3§ | 5.3 ± 4.4§ | 3.0 ± 3.1§ | .06 |
| Lymphocytes/nL, n = 46 | 50.2 ± 61.0§ | 51.2 ± 65.7§ | 46.6 ± 42.4§ | NS |
| Monocytes/nL; n = 46 | 1.4 ± 2.6§ | 1.5 ± 2.9§ | 1.1 ± 1.1§ | NS |
| CD38+ leukemia (%), n = 47 | 24 (51) | 17 (46) | 7 (70) | NS |
| ZAP-70+ leukemia (%), n = 42 | 19 (45) | 15 (45) | 4 (44) | NS |
| β2-microglobulin, mg/L, n = 45 | 4.0 ± 2.2§ | 3.8 ± 2.0§ | 5.0 ± 2.5§ | NS |
| Thymidine kinase, U/L, n = 32 | 28.5 ± 34.5§ | 22.3 ± 29.3§ | 55.8 ± 44.8§ | .055 |
In most patients, the laboratory parameters were not determined at diagnosis, but during the course of the disease. Normal ranges are as follows: hemoglobin, 14.0 to 18.0 g/dL (male), 12.0 to 14.0 g/dL (female); platelets, 140 to 440/nL; leukocytes, 4.0 to 10.0/nL; neutrophils, 1.5 to 7.0/nL; lymphocytes, 1.0 to 4.0/nL; monocytes, less than 1.0/nL; β2-microglobulin, less than 3.5 mg/L; and thymidine kinase less than 7 U/L. CD38+ or ZAP-70+ leukemias were diagnosed when more than 20% of the leukemic cells expressed the respective marker.
NS indicates not significant.
Comparison between the HLA-G-positive and HLA-G-negative subgroups using the chi-square test (Binet stage, CD38+ and ZAP-70+ leukemias) or the Mann-Whitney U test (all other variables).
Median (range).
Percent of all patients. Because of rounding, percentages do not always add up to 100.
Mean ± standard error of the mean.